NCT06761144 Pulmonary Thromboembolism in Cancer Patients: Early Rule-out From the Emergency Department
| NCT ID | NCT06761144 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Pulmonary Thromboembolisms |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-07-13 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2024-07-13 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pulmonary thromboembolism is a frequent complication of cancer; in some cases, it is diagnosed occasionally during diagnostic examinations as part of the regular follow-up of the disease. Not all patients diagnosed with thromboembolism present symptoms; therefore, after appropriate investigations during observation in the emergency room and/or a short hospitalisation in Emergency Medicine, they could be discharged home, avoiding lengthy hospitalisations that would have a considerable impact on their health and psychological condition. The goal of this observational study is to compare the efficacy of several assessment scales for use by physicians to identify patients at low risk of developing serious complications of pulmonary embolism within 30 days of diagnosis, in order to be able to identify a group of low-risk patients who could be discharged early from the emergency department/emergency medicine safely. What does participation in this study entail compared to the normal care you receive and what are your responsibilities as a participant? At the time of patient enrolment in the emergency room/emergency medicine, the data necessary for the calculation of 6 scoring systems will be collected, which will take approximately 5 minutes. The patient enrolled in the study will be contacted by telephone in order to assess the state of health; the call will take approximately 1 minute and will take place 30 days after access to the emergency room. Participation in the study does not entail any obligation or restriction, nor will it be charged for.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of pulmonary embolism (symptomatic and/or incidental) * Active onco-haematological disease (disease followed in oncological/haematological and/or metastatic setting) * Informed consent to the study Exclusion Criteria: * Patients returning to the Emergency Department for complications related to previously diagnosed pulmonary embolism
Contact & Investigator
Eleonora Tubertini, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06761144 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Thromboembolisms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06761144 currently recruiting?
Yes, NCT06761144 is actively recruiting participants. Contact the research team at eleonora.tubertini@aosp.bo.it for enrollment information.
Where is the NCT06761144 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06761144 clinical trial?
NCT06761144 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Eleonora Tubertini, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 500 participants.